A Successful Fiscal Year 2025 for the University Hospital of Basel
The University Hospital of Basel (USB) once again posted a positive result in fiscal year 2025, with a consolidated net income of 6.6 million Swiss francs. At the same time, a historic step is shaping the future of the regional healthcare system: In November 2025, the USB acquired the Claraspital, thereby strengthening its role as a regional hub and enhancing access to cutting-edge medical care for northwestern Switzerland.
2026-04-09, 10:00
The USB closed the 2025 fiscal year with a consolidated net income of CHF 6.6 million. The public-law institution University Hospital Basel (USB) generated a profit of CHF 3.6 million in 2025 (previous year: CHF 0.2 million). Thanks to the acquisition of Claraspital, the USB can now forgo the construction of Clinic 3. The accumulated investments in the planning of Clinic 3 were therefore written off. Excluding this one-time item, the profit generated at the consolidated level would have been 19.1 million Swiss francs (16.1 million Swiss francs for hospital operations at the USB).
Demand at a Record High, Trust as a Benchmark
The EBITDAR margin stood at 7.2% in fiscal year 2025, significantly higher than in previous years. Gross revenue from inpatient care rose by 6.7% compared to the previous year, while the 10.7% increase in outpatient revenue stands out in particular—an indicator that underscores the USB’s status as the hospital of choice in northwestern Switzerland. Throughout the year, 64,000 inpatient cases were treated at the hospital facilities. “We owe this strong result to the tremendous dedication of our employees and the ongoing improvement of our processes,” says Robert-Jan Bumbacher, Chairman of the Board of Directors at USB.
However, the operating environment remains challenging. Reimbursement rates for inpatient and outpatient services still do not cover costs in many areas. Furthermore, the new TARDOC outpatient fee structure, set to be introduced in 2026, increases the complexity of billing and will result in lower revenues for various medical specialties, which could lead to underfunding.
Strategic Milestone: Acquisition of Claraspital
The year 2026 is marked by the acquisition of Claraspital. This acquisition specifically improves healthcare provision in the region and unlocks additional synergies. By consistently strengthening Claraspital’s already well-developed infrastructure, USB is utilizing its resources more efficiently across all its locations. “This allows us to gain highly qualified staff and integrate a facility with well-established processes and an excellent corporate culture,” says Hospital Director Dr. Rakesh Padiyath.
Comprehensive Cancer Center: A Quantum Leap for Cancer Care
The centerpiece of the Claraspital campus will be the new Comprehensive Cancer Center (CCC). Oncology care will be consolidated under one roof to offer cancer patients in northwestern Switzerland world-class treatment close to home. “This will represent a quantum leap for oncology in northwestern Switzerland,” says Hospital Director Dr. Rakesh Padiyath.
Media Information Office